Abstract
There are three major difficulties hindering the development of a vaccine for malaria. First, for all three stages of the parasite life cycle there is an incomplete understanding of the precise type of immune response to aim for. Second, only a handful of the many hundreds of parasite-derived antigens have been explored, and though several have been shown to be protective in animal models, it is not known if they are the most potent. Third, there is strong evidence that the parasite can evade host immunity, for example by antigenic variation. In this brief article, John Playfair and his colleagues address mainly the first issue and suggest that complete resistance to infection is probably not feasible, and that attention should be directed not so much at vaccines designed to eliminate one or other stage of the parasite, but rather towards the possibility of an ‘antitoxic’ vaccine that prevents the serious pathological complications of the disease.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.